Corixa Corporation is a company.
Key people at Corixa Corporation.
Corixa Corporation was founded by Mark McDade (Co-founder and COO).
Corixa Corporation was founded by Mark McDade (Co-founder and COO).
Corixa Corporation was a Seattle-based biotechnology company founded in 1994, focused on developing immunotherapeutics to treat and prevent autoimmune diseases, infectious diseases, and cancer by harnessing the immune system.[1][2][4] It specialized in adjuvants like MPL (Monophosphoryl lipid A), a derivative of lipid A used in vaccines, and operated facilities in Seattle and Hamilton, Montana, before its acquisition by GlaxoSmithKline (GSK) in 2005, after which it ceased independent operations in 2006.[1]
The company targeted unmet needs in immunology, with drug candidates such as DTS-201 for prostatic cancer, RC-552 for myocardial ischemia, and others for plaque psoriasis and myasthenia gravis, though most pipelines were discontinued post-acquisition.[3] Corixa served pharmaceutical partners and patients through collaborative trials, notably with GSK and Stanford University, but lacked ongoing growth as a standalone entity after integration into GSK's portfolio.[1][3]
Corixa emerged in 1994 from Seattle's burgeoning biotech scene, likely spinning out of local research ecosystems tied to the University of Washington, with a mission to direct the immune system against major diseases.[1][4] Key details on specific founders are sparse in available records, but the company quickly established labs in Seattle and a production site in Hamilton, Montana, building early traction through adjuvant technology like MPL, which drew interest from major pharma players.[1][2]
Pivotal moments included partnerships for clinical trials starting in 2004 with entities like Stanford and GSK, culminating in GSK's full acquisition in 2005 to leverage Corixa's MPL for vaccine enhancement.[1][3] This marked the end of its independent journey, folding its assets into a global giant by 2006.[1]
Corixa rode the 1990s-2000s biotech wave emphasizing immunotherapy and adjuvants, amid rising demand for targeted treatments beyond traditional chemo for cancer and autoimmunity.[1][2] Timing was ideal post-HIV/AIDS era, when immune modulation gained traction, and its MPL tech influenced vaccine development—GSK incorporated it into products like their shingles vaccine, amplifying impact.[1]
Market forces favoring Corixa included biotech M&A booms, with Big Pharma acquiring innovative platforms to bolster pipelines amid patent cliffs.[1] It shaped Seattle's biotech hub, contributing to the ecosystem alongside UW-affiliated startups, though its defunct status limits ongoing influence—legacy endures in adjuvant standards.[1][4]
As a defunct entity since 2006, Corixa's trajectory peaked with GSK acquisition, embedding its MPL adjuvant into enduring vaccines and therapies.[1] No independent revival is possible, but its tech persists within GSK, potentially evolving with modern mRNA and oncology trends.
Shaping factors include adjuvant advancements in personalized medicine; influence may grow indirectly as GSK leverages it in next-gen immunotherapies, tying back to Corixa's core bet on immune-directed innovation.[1][3]
Key people at Corixa Corporation.
